Skip to main content
. 2019 Jan 11;17:14. doi: 10.1186/s12957-018-1554-8

Table 4.

Complications after CRS and HIPEC

Experimental group N = 8 Control group N = 88
Cardiovascular 1 (12.5%) 20 (18.1%)
Pulmonary 2 (25%) 12 (10.9%)
Gastrointestinal 3 (37.5%) 31 (28.2%)
Sepsis/SIRS 2 (25%) 9 (8.1%)
Mental 1 (12.5%) 12 (10.9%)
Wound 2 (25%) 7 (6.4%)
Anastomotic leakage 0 (0%) 8 (7.2%)
Neurological 1 (12.5%) 2 (1.8%)
Nephrological 0 (0%) 19 (17.3%)

CRS cytoreductive surgery, HPEC hyperthermic intraperitoneal chemotherapy